InflaRx to Report Phase 2a Results for Oral C5aR Inhibitor INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Key Insights
InflaRx (search) will announce topline data from its Phase 2a clinical trial of oral C5aR (search) inhibitor INF904 in patients with hidradenitis suppurativa (search) and chronic spontaneous urticaria (search) on November 10, 2025.
The company will host a webcast at 8:00 AM EST featuring key opinion leader insights to discuss the clinical data results.
INF904 represents an orally administered small molecule inhibitor targeting C5a (search)-induced signaling via the C5a receptor, part of InflaRx (search)'s complement system-focused therapeutic platform.
InflaRx (search) N.V. (Nasdaq: IFRX) announced it will report topline data from the Phase 2a clinical trial of its oral C5aR (search) inhibitor INF904 in patients with hidradenitis suppurativa (search) (HS) and chronic spontaneous urticaria (search) (CSU) on Monday, November 10, 2025. The biopharmaceutical company, which specializes in anti-inflammatory therapeutics targeting the complement system, will release the data in a pre-market press release.
Clinical Trial Data Presentation
The company will host a webcast and conference call on November 10, 2025, at 8:00 AM EST / 2:00 PM CET to discuss the topline clinical data. The presentation will be accompanied by slides and will feature key opinion leader insights. Participants can pre-register to receive an invite link and dial-in details, while the live webcast and audio archive will be accessible on the InflaRx (search) website.
INF904 Development Program
INF904 is an orally administered small molecule inhibitor of C5a (search)-induced signaling via the C5a receptor. This therapeutic approach targets C5a, which the company describes as "a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases." The oral formulation represents a potentially convenient administration route for patients with these chronic inflammatory conditions.
InflaRx's Complement-Focused Platform
InflaRx (search) applies proprietary anti-C5a (search) and anti-C5aR (search) technologies to discover, develop and commercialize inhibitors of the complement activation factor C5a and its receptor, C5aR. The company has also developed vilobelimab, a first-in-class, anti-C5a monoclonal antibody that is delivered intravenously. Vilobelimab selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.
Corporate Background
Founded in 2007, InflaRx (search) maintains offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, Michigan. The company will also publish its third quarter 2025 financial and operating results via Form 6-K on the same day as the clinical data announcement.